Cpwm LLC lifted its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 19.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,774 shares of the medical research company’s stock after acquiring an additional 1,451 shares during the period. Cpwm LLC’s holdings in Amgen were worth $1,526,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of AMGN. Jackson Grant Investment Advisers Inc. grew its position in Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 5 shares in the last quarter. South Texas Money Management Ltd. grew its position in Amgen by 0.7% in the second quarter. South Texas Money Management Ltd. now owns 3,223 shares of the medical research company’s stock valued at $555,000 after purchasing an additional 22 shares in the last quarter. Glenview Trust Co grew its position in Amgen by 0.4% in the second quarter. Glenview Trust Co now owns 6,137 shares of the medical research company’s stock valued at $1,057,000 after purchasing an additional 25 shares in the last quarter. Roberts Glore & Co. Inc. IL grew its position in Amgen by 0.4% in the second quarter. Roberts Glore & Co. Inc. IL now owns 7,425 shares of the medical research company’s stock valued at $1,279,000 after purchasing an additional 27 shares in the last quarter. Finally, WMS Partners LLC lifted its stake in Amgen by 0.5% in the second quarter. WMS Partners LLC now owns 6,319 shares of the medical research company’s stock valued at $1,088,000 after acquiring an additional 33 shares during the last quarter. 79.53% of the stock is owned by institutional investors.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total value of $265,624.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 4,575 shares of company stock valued at $838,064 in the last quarter. Corporate insiders own 0.19% of the company’s stock.
Shares of NASDAQ AMGN traded down $3.86 during mid-day trading on Friday, reaching $168.14. 3,747,770 shares of the company were exchanged, compared to its average volume of 4,476,543. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49. The stock has a market cap of $121,155.30, a PE ratio of 13.37, a P/E/G ratio of 2.06 and a beta of 1.36. Amgen, Inc. has a twelve month low of $152.16 and a twelve month high of $201.23.
Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). Amgen had a return on equity of 30.87% and a net margin of 8.66%. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. During the same quarter in the prior year, the business posted $2.89 EPS. The business’s quarterly revenue was down 2.7% compared to the same quarter last year. analysts predict that Amgen, Inc. will post 13.25 EPS for the current fiscal year.
Amgen announced that its Board of Directors has authorized a stock repurchase program on Thursday, February 1st that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s leadership believes its shares are undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be paid a $1.32 dividend. This represents a $5.28 annualized dividend and a yield of 3.14%. The ex-dividend date is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is 41.97%.
A number of brokerages have commented on AMGN. ValuEngine cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Monday, April 2nd. Barclays cut their price target on shares of Amgen from $190.00 to $180.00 and set an “equal weight” rating for the company in a research note on Thursday. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $194.00 price target for the company in a research note on Thursday. Oppenheimer set a $205.00 price target on shares of Amgen and gave the company a “buy” rating in a research note on Friday, January 5th. Finally, BidaskClub cut shares of Amgen from a “hold” rating to a “sell” rating in a research note on Saturday, March 24th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $190.57.
TRADEMARK VIOLATION WARNING: “Amgen, Inc. (AMGN) Holdings Boosted by Cpwm LLC” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/08/amgen-inc-amgn-shares-bought-by-cpwm-llc.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.